Table 2 MMP3 genotypes vs clinical, pathological and epidemiological variables
Variables | MMP3 -1171 5A/6A | |||
|---|---|---|---|---|
| Â | 5A5A | 5A6A | 6A6A | p-value* |
Stage at Diagnosis | Â | Â | Â | Â |
   0 | 9 (16%) | 36 (63%) | 12 (21%) |  |
   I | 96 (19%) | 238 (48%) | 162 (33%) |  |
   II | 32 (14%) | 124 (54%) | 75 (33%) |  |
   III | 27 (16%) | 81 (49%) | 57 (35%) |  |
   IV | 2 (22%) | 5 (56%) | 2 (22%) | 0.36 |
Primary Clark Level | Â | Â | Â | Â |
   I | 9 (16%) | 36 (63%) | 12 (21%) |  |
   II | 22 (21%) | 54 (51%) | 29 (28%) |  |
   III | 28 (19%) | 73 (49%) | 47 (32%) |  |
   IV | 72 (15%) | 241 (50%) | 165 (35%) | 0.36 |
   V | 9 (13%) | 39 (57%) | 21 (30%) | 0.04 £ |
Thickness (mm) | Â | Â | Â | Â |
   In situ | 9 (16%) | 36 (63%) | 12 (21%) |  |
   < 1.01 | 60 (19%) | 150 (48%) | 105 (33%) |  |
   1.01 – 2.00 | 45 (17%) | 132 (49%) | 90 (34%) |  |
   2.01 – 4.00 | 28 (18%) | 78 (49%) | 53 (33%) |  |
   > 4.00 | 12 (10%) | 71 (60%) | 35 (30%) | 0.16 |
TILs | Â | Â | Â | Â |
   Absent | 28 (14%) | 101 (50%) | 73 (36%) |  |
   Non-brisk | 65 (17%) | 208 (54%) | 114 (30%) | 0.32 |
   Brisk | 4 (13%) | 20 (65%) | 7 (23%) | 0.04 £ |
Distant Metastasis | Â | Â | Â | Â |
   Yes | 21 (16%) | 69 (54%) | 39 (30%) |  |
   No | 148 (17%) | 428 (50%) | 277 (33%) | 0.84 |
Intransit Metastasis | Â | Â | Â | Â |
   No | 160 (17%) | 468 (51%) | 296 (32%) |  |
   Yes | 6 (22%) | 12 (44%) | 9 (33%) | 0.80 |
Number of Moles | Â | Â | Â | Â |
   None | 41 (16%) | 136 (53%) | 79 (31%) |  |
   Few | 87 (18%) | 240 (49%) | 165 (34%) |  |
   Moderate | 27 (17%) | 87 (54%) | 48 (30%) |  |
   Many | 9 (23%) | 21 (53%) | 10 (25%) | 0.76 |
Phenotypic Index | Â | Â | Â | Â |
   1 (low risk) | 6 (16%) | 15 (41%) | 16 (43%) |  |
   2 | 28 (14%) | 105 (51%) | 73 (35%) |  |
   3 | 59 (19%) | 157 (50%) | 98 (31%) |  |
   4 | 59 (18%) | 172 (54%) | 89 (28%) |  |
   5 (high risk) | 18 (18%) | 47 (46%) | 38 (37%) | 0.36 |